Avid Bioservices Inc risk profile
97 Acute at or past the historical limit
Measured 1 September 2026 from CDMO's filed statements. Recomputed nightly.
97 (Acute), driven by Operating pressure at 100, over 3 weighted categories on the GENERAL profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | Reads pct_below_52w_high, volatility_1y_pct and avg_turnover_90d_usd. No reading is stored for this company. | |||
| Operating pressure | 100 | Acute | Stable | Costs outgrowing revenue — +15.1 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — 2.90x |
| Leverage and coverage | 90 | Acute | Worsening | Net debt to EBITDA |
| Competitive position | Reads research_and_development, operating_income, revenue, peer cohort and disclosed transition KPIs. No reading is stored for this company. | |||
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Financials, valuation and price history for Avid Bioservices Inc